In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cosmetics Ad Enforcement In Brief: TreSemme Naturals Settlement; Julep Beauty; More

This article is powered by The Rose Sheet

Executive Summary

Unilever has established a $3.25m fund to recompense consumers for TreSemme Natural purchases under an approved class-action settlement in California’s Eastern District. Meanwhile, Washington state’s attorney general has deceptive negative-option marketing in his sights, and consumer watchdog groups are urging FTC to tackle undisclosed influencer advertising in the social media channel.

Advertisement

Related Content

‘Hypoallergenic’ Class Actions Bubbling Up: The New ‘Natural’ Scourge?
Chemist Romanowski On 'Natural' Beauty Evolution, Current Challenges
FTC Wins Around $73M From Defendants Behind ‘Risk-Free’ Skin-Care Trials
Ad Watchdog Reports Kardashians To FTC For Deceptive Instagram Posts
California Suit Challenges Unilever On Naturalness Of TRESemme Line

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

RS108631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel